Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

73.65 -0.87 (-1.17%)
Official Closing Price Updated: 7:00 PM EST, Feb 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
27 28 29 30 31 32 33 34 Next >
The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 14) Alexion Pharmaceuticals,... 
Via Benzinga
Topics Product Recall
Exposures Legal Product Safety
XOMA Buys Royalty, Milestone Interest In Checkmate's Vidutolimod From Kuros Biosciences
XOMA Corporation (NASDAQ: XOMA) has acquired the royalty interest position Kuros Biosciences holds in Checkmate Pharmaceuticals Inc's (NASDAQ:... 
Via Benzinga
Dialing For Stocks
Thanks to Fed Chairman Powell, markets brushed off worrying about inflation today. 
Via Talk Markets
Topics Economy
Exposures Interest Rates
Selloff Round 3
Stocks fell across the board in foreign countries, except for Britain which was upbeat. 
Via Talk Markets
Analyzing Bristol-Myers Squibb's Unusual Options Activity
Shares of Bristol-Myers Squibb (NYSE:BMY) saw some unusual options activity on Tuesday. Following the unusual option alert, the stock price moved down to $67.26. Sentiment:... 
Via Benzinga
Can Gilead Beat Bristol Myers Squibb With Its Cancer CAR-T Therapy?
The battle for market share could come down to which drug has the lesser side effects. 
Via The Motley Fool
Recovery Friday
The big winners this week were Financials. 
Via Talk Markets
Unusual Options Activity Insight: Bristol-Myers Squibb
Bristol-Myers Squibb (NYSE:BMY) shares experienced unusual options activity on Friday. The stock price moved up to $67.41 following the option alert. Sentiment: BEARISH Option... 
Via Benzinga
Top 5 Stocks To Buy For July 2021
Discussion and analysis on my top five stocks for July 2021: BMY, ENB, HBAN, LMT and PNW. 
Via Talk Markets
After Second Look Oncopeptides' Melflufen Wins Head-To-Head Myeloma Trial, But Difference In OS Triggers FDA Hold
Oncopeptides AB (OTC: ONPPF) has some good news and some bad news from the updated results from Phase 3 OCEAN study of Pepaxto (melflufen) plus dexamethasone in... 
Via Benzinga
Exposures Product Safety
Jim Lebenthal Likes AbbVie Stock At Its Current Price
It's a great time to invest in pharmaceutical companies such as AbbVie Inc (NYSE: 
Via Benzinga
OncoSec Stock Jumps On Anti-Cancer Gene Therapy Trial Collaboration With Merck In Melanoma
OncoSec Medical Inc (NASDAQ: ONCS) will evaluate its DNA-plasmid interleukin-12 (IL-12) TAVO (tavokinogene telseplasmid) with Merck & Co Inc's (NYSE: MRK)... 
Via Benzinga
Lots Of Deal News
Today Didi, a Chinese ride-hailing stock is doing its IPO reportedly at above the level projected in its application. 
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
Global Glioblastoma Multiforme (GBM) Treatment Market Could Reach Nearly $1.8 Billion By 2027
Via FinancialNewsMedia
Will This 2020 Biotech IPO Crush the Market This Year?
Legend Biotech's CAR-T therapy's trial results were amazing, and could earn the treatment FDA approval in 2021. 
Via The Motley Fool
Topics Initial Public Offering
Exposures Product Safety Securities Market
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the Treatment of Mismatch Repair Deficient or Microsatellite Instability–High Metastatic Colorectal Cancer After Prior Chemotherapy
From Bristol Myers Squibb
Via Business Wire
The Daily Biotech Pulse: Roche Gets Authorization For COVID-19 Treatment, Nods For Sanofi-Regeneron In Europe, Osmotica Divestment, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 24) AngioDynamics, Inc. (NASDAQ... 
Via Benzinga
Exposures COVID-19
Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) as Adjuvant Treatment for Esophageal or Gastroesophageal Junction Cancer Patients with Residual Pathologic Disease Following Chemoradiotherapy
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Receives Positive CHMP Opinion for Anti-BCMA CAR T Cell Therapy Abecma (idecabtagene vicleucel) for Relapsed and Refractory Multiple Myeloma
From Bristol Myers Squibb
Via Business Wire
Wednesday Is A Normal Day
Meme stocks Gamestop and Torchlight Energy both did share sales to cash in on their share price rises. 
Via Talk Markets
14 Biotech Stocks To Watch Over The Next 6 Months
Biotechs are at the mercy of several make-or-break catalysts that invariably have a big impact on stocks. A case in point was the strong upside in Biogen Inc.'s (NASDAQ:... 
Via Benzinga
Which Is A Better Investment? Amgen Vs Bristol-Myers Squibb… The Winner May Surprise You
Both companies have the same yield, at right about 2.9%. They've also both been increasing their dividends for almost the same exact length of time - 12 years for Bristol-Myers Squibb versus 11 years... 
Via Talk Markets
The 2 Best Pharma Stocks to Buy on Dips
Because the COVID-19 pandemic is under control in most major economies, the hype surrounding vaccine producers is gradually tapering off. 
Via Talk Markets
Exposures COVID-19
10 Health Care Stocks Showing Unusual Options Activity In Today's Session
This unusual options alert can help traders track potentially big trading opportunities. Traders often look for circumstances when the market estimation of an option diverges away... 
Via Benzinga
Healthcare Portfolio Playbook: Time To Rebalance With MedTech
As we look to re-balance our portfolio in the near-term, investors should consider adding Medtech as we have suggested in the past. Though, more recently, we have also focused on large-cap... 
Via Talk Markets
Bristol Myers Onureg Scores European Approval As Maintenance Therapy For Acute Myeloid Leukemia
The European Commission has granted full marketing authorization to Bristol Myers Squibb & Co's (NYSE: BMY) Onureg (azacitidine tablets) The approval... 
Via Benzinga
Bristol Myers Squibb Receives European Commission Approval for Onureg® (azacitidine tablets) as Frontline Oral Maintenance Therapy for Adults with Acute Myeloid Leukemia
From Bristol Myers Squibb
Via Business Wire
The Daily Biotech Pulse: Orphazyme Falters At FDA, Athira's CEO Placed On Temporary Leave, 5 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 17) 10x Genomics, Inc. (NASDAQ... 
Via Benzinga
Exposures Product Safety
Bristol Myers Inks Licensing Pact For Eisai's Folate Receptor ADC Drug, Lays Out Over $3B For Rights
Eisai Co Ltd (OTC: ESALY) and Bristol-Myers Squibb Co (NYSE: BMY) have entered into an exclusive global strategic collaboration agreement for the co-... 
Via Benzinga
Eisai and Bristol Myers Squibb Enter Into Global Strategic Collaboration for Eisai’s MORAb-202 Antibody Drug Conjugate
From Bristol Myers Squibb
Via Business Wire
< Previous 1 2
...
27 28 29 30 31 32 33 34 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.